When was TAI Diagnostics founded?

TAI Diagnostics was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Where is TAI Diagnostics located?

TAI Diagnostics is headquartered in Milwaukee, United States. It is registered at Racine, Wisconsin.

How many employees does TAI Diagnostics have?

As of Dec 31, 2022, the latest employee count at TAI Diagnostics is 30.

Is TAI Diagnostics a funded company?

TAI Diagnostics is a funded company, having raised a total of $21.1M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 23, 2015.

When was the latest funding round of TAI Diagnostics?

TAI Diagnostics' latest funding was a $***** Series A round on Jun 28, 2018, with participation from 1 investor.

Where does TAI Diagnostics rank among its competitors?

TAI Diagnostics ranks 71st amongst 159 active competitors, of which 59 are funded. It stands 14th in terms of total funding among its competitors.

Who are the top competitors of TAI Diagnostics?

TAI Diagnostics' top competitors include Guardant Health, GRAIL and BillionToOne. Among them, TAI Diagnostics secured the most recent funding round in June, 2018.

TAI Diagnostics - 2025 Company Profile, Team, Funding & Competitors

Company Details

Provider of diagnostic solutions for transplant patients. Its flagship product is a non-invasive blood test that can be used to monitor if heart transplant patients are rejecting the new organ by measuring the levels of cell-free DNA originating from the transplanted organ in the patient's blood. Its founding team was previously involved with Ariosa Diagnostics, which was acquired by Roche.

Website: taidiagnostics.com
Registered Address: Racine, Wisconsin

Key Metrics

Founded Year

2013

Location

Milwaukee, United States

Stage

Series A

Total Funding

$21.1M in 2 rounds

Latest Funding Round

Series A, Jun 28, 2018, $*****

Investors

Venture Investors & 2 more

Ranked

71^st among 159 active competitors

Employee Count

30 as on Dec 31, 2022

Similar Companies

Guardant Health & 152 more

View TAI Diagnostics' full profile

TAI Diagnostics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TAI DIAGNOSTICS CIN: 464742850 , United States, Active	Dec 26, 999	-	30 (As on Dec 31, 2022)	-

TAI Diagnostics has raised a total funding of $21.1M over 2 rounds. Its first funding round was on Oct 23, 2015. Its latest funding round was a Series A round on Jun 28, 2018 for $*****. 1 investor participated in its latest round. TAI Diagnostics has 3 institutional investors.

Here is the list of recent funding rounds of TAI Diagnostics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 28, 2018	5213297	Series A	3841115	9147232	6044027	7211428
Oct 23, 2015	2776567	Series A	5359369	1632774	Venture Investors	3395600

Access funding benchmarks and valuations. Sign up today!

View details of TAI Diagnostics's funding rounds and investors

TAI Diagnostics' employee count trend

TAI Diagnostics has 30 employees as of Dec 22. The total employee count is 9.0% lower than what it was in Dec 21. Here is TAI Diagnostics's employee count trend over the years:

Employee count trend for TAI Diagnostics

Uncover TAI Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TAI Diagnostics include Guardant Health, GRAIL and BillionToOne. Here is the list of Top 10 competitors of TAI Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Orbimed, Sequoia Capital & 23 others	80/100
2nd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$3.22B	Arch Venture Partners, CPP Investments & 47 others	79/100
3rd	BillionToOne 2015, San Francisco (United States), Series D	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 29 others	67/100
4th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	Orbimed, DFJ Growth & 17 others	65/100
5th	Mirvie 2019, San Francisco (United States), Series B	Provider of non-invasive diagnostic tests for pregnant women	$114M	Decheng Capital, Mayfield & 10 others	62/100
6th	Nucleix 2008, Rehovot (Israel), Series C	Developer non-invasive molecular cancer diagnostic tests	$85.5M	RA Capital Management, Sands Capital & 10 others	60/100
7th	Naveris 2017, Waltham (United States), Series A	Provider of blood tests for early cancer detection	$68.5M	Gurnet Point Capital, MIT Alumni Angels of Boston ... & 2 others	59/100
8th	Saga Diagnostics 2016, Lund (Sweden), Series A	Provider of tests for detection and analysis of circulating tumor DNA	$17.9M	Hadean Ventures, LU Innovation & 11 others	58/100
9th	Scipher Medicine 2014, Waltham (United States), Series D	Provider of precision medicine based on liquid biopsy test	$233M	Northpond Ventures, Cowen & 14 others	58/100
10th	Precede 2021, Boston (United States), Series C	Liquid-biopsy platform for cancer diagnosis	$57M	5AM Ventures, Lilly Asia Ventures & 6 others	58/100
71st	TAI Diagnostics 2013, Milwaukee (United States), Series A	Provider of diagnostic solutions for transplant patients	$21.1M	Venture Investors, United Therapeutics & 1 others	38/100